Previous 10 | Next 10 |
PAVmed ( PAVM ) has a collection of products that are in various states of regulatory clearance, but taken together these have a market opportunity in the billions of dollars. While good progress has been made, the company's immediate commercialization efforts for three of its products (EsoG...
Recon Technology (NASDAQ: RCON ) -38% on ~$2.1M registered direct offering . More news on: Recon Technology, Ltd., Geron Corporation, Syndax Pharmaceuticals, Inc., Stocks on the move, , Read more ...
PAVmed Inc. (PAVM) Q1 2020 Results Earnings Conference Call May 21, 2020, 04:30 PM ET Company Participants Mike Havrilla - Director of IR Lishan Aklog - Chairman and CEO Dennis McGrath - President & Chief Financial Officer Conference Call Participants Anthony Vendetti -...
Conference call to be held today at 4:30 p.m. Eastern time NEW YORK, May 21, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today reported preliminary fi...
NEW YORK, May 11, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the Company will host a business update conference call on Thursday, May...
Stemline Therapeutics (NASDAQ: STML ) +151% on Menarini bid . More news on: Stemline Therapeutics, Inc., Applied DNA Sciences, Inc., KLX Energy Services Holdings, Inc., Stocks on the move, , Read more ...
PAVmed Receives FDA Approval for Carpal Tunnel Device PAVmed ( PAVM ) reported that the FDA has given its approval for its CarpX device. It is a single use tool which is used for treating carpal tunnel syndrome and is minimally invasive. With this approval, PAVmed may now market the produc...
Since my last article on PAVmed (PAVM) on September 26, PAVM's share price tripled to a little over $3 late February before falling back a little to about $2.60 today, presenting another buying opportunity based on FDA approval of CarpX on April 21, and other upcoming catalysts involving pro...
The FDA has granted 510(k) clearance for PAVmed's ( PAVM +14.5% ) single-use CarpX minimally invasive carpal tunnel device that the company says dramatically reduces recovery time compared to traditional open surgery. More news on: PAVmed Inc., Healthcare stocks news, Stocks on the m...
NEW YORK, April 21, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced it has received 510(k) marketing clearance from the U.S. Food and Drug Admi...
News, Short Squeeze, Breakout and More Instantly...
Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume PR Newswire Quarterly EsoGuard ® test volume increased 31 percent sequentially NEW YORK , July 23, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("L...
Lucid Diagnostics Launches New Corporate Website PR Newswire NEW YORK , July 11, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and majority-ow...
Lucid Diagnostics Announces Positive Data from its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population PR Newswire Prospective screening study demonstrates excellent EsoGuard s...